首页> 外文期刊>Rheumatology international. >Systemic sclerosis with anti-RNA polymerase III positivity following silicone breast implant rupture: possible role of B-cell depletion and implant removal in the treatment
【24h】

Systemic sclerosis with anti-RNA polymerase III positivity following silicone breast implant rupture: possible role of B-cell depletion and implant removal in the treatment

机译:硅氧烷乳腺植入物破裂后抗RNA聚合酶III阳性的全身硬化:B细胞耗尽和植入治疗中的植入物的作用

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Despite some case reports and small series of women with silicone breast implants (SBI) developing Systemic Sclerosis (SSc), no clear evidence of an association of SBI with SSc is available. However, SSc is characterized by clinical and immunological heterogeneity and autoantibodies are currently the best markers to stratify this heterogeneity of patients. Therefore, we have reviewed the literature for details of autoantibody characterization in reports of SSc associated with SBI. Moreover, the case of an anti-RNA polymerase III-positive SSc with rapid onset and progression, in which SBI rupture was found is described. This case may support a previous observation suggesting a possible role of SBI rupture as a trigger for anti-RNA polymerase III-positive SSc. This possible causal role may be reinforced by the observation that in our patient, despite immunosuppressive treatment, the disease progressed until SBI were removed, and reduction of anti-RNA polymerase III titer was obtained after rituximab treatment. This result may support data suggesting that B-cell depleting therapy may decrease specific autoantibody level in SSc patients, and that these changes are associated with disease improvement.
机译:尽管某些案例报告和小型系列含有硅乳蛋白植入物(SBI)的妇女,但均发育全身硬化(SSC),目前没有明确的证据表明SBI与SSC的关联。然而,SSC的特征在于临床和免疫异质性,自身抗体是目前最好的标记,以分层这种患者的这种异质性。因此,我们审查了文献,了解与SBI相关的SSC的报告中的自身抗体表征的细节。此外,描述了具有快速发作和进展的抗RNA聚合酶III阳性SSC的情况,其中发现了SBI破裂。这种情况可以支持先前的观察,表明SBI破裂作为抗RNA聚合酶III阳性SSC的触发的可能作用。这种可能的因果作用可能通过观察结果来加强,在我们的患者中,尽管免疫抑制治疗,但疾病进展直到除去SBI,并且在Rituximab处理后获得抗RNA聚合酶III滴度的减少。该结果可以支持数据表明B细胞耗尽治疗可能降低SSC患者的特异性自身抗体水平,并且这些变化与疾病改善有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号